RLS Radiopharmacies has entered a strategic agreement with Eckert & Ziegler, which will see all 31 of RLS’s radiopharmacies equipped with Eckert & Ziegler’s GalliaPharm generators.
The RLS radiopharmacy network will use these generators to produce gallium-68-based (Ga-68) radiopharmaceuticals for PET imaging and treatment planning for patients with neuroendocrine tumors and prostate cancer.
To date, RLS has installed Eckert & Ziegler’s GalliaPharm generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June 2024.
RLS added that it is also building a national distributed radiopharmaceutical contract development and manufacturing network. With this, 80,000 sq ft of space across eight of its pharmacies will be used for radiopharmaceutical development, manufacturing, and the production of medical isotopes such as gallium-68, actinium-225, and lutetium-177.
